Reduced in vivo toxicity of doxorubicin by encapsulation in cholesterol-containing self-assembled nanoparticles
- 1 May 2016
- journal article
- Published by Elsevier in Pharmacological Research
- Vol. 107, 93-101
Abstract
No abstract availableKeywords
Funding Information
- University of Connecticut Academic Plan Grant
- Colombian Department of Sciences and Technology
This publication has 37 references indexed in Scilit:
- Palmar-Plantar Erythrodysesthesia Associated with Chemotherapy and Its TreatmentCase Reports in Oncology, 2011
- Role of Block Copolymer Nanoconstructs in Cancer TherapyCritical Reviews™ in Therapeutic Drug Carrier Systems, 2009
- Liposome‐encapsulated doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab in patients with lymphoma and concurrent cardiac diseases or pre‐treated with anthracyclinesHematological Oncology, 2007
- Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome)Annals of Oncology, 2007
- Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicityToxicology, 2005
- Dose Dependency of Pharmacokinetics and Therapeutic Efficacy of Pegylated Liposomal Doxorubicin (DOXIL) in Murine ModelsJournal of Drug Targeting, 2002
- Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinomaCancer, 2001
- Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2Annals of Oncology, 2000
- Doxorubicin-Induced CardiomyopathyNew England Journal of Medicine, 1998
- Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400 mg/m2: Evidence for enhanced toxicity with multiagent chemotherapyAmerican Journal of Hematology, 1991